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Abstract 
PURPOSE: A large panel gene expression analysis was conducted to identify 
biomarkers associated with effectiveness of adding palbociclib to fulvestrant.  
METHODS: PALOMA-3 randomized 521 endocrine-pretreated metastatic 
breast cancer patients to receive palbociclib+fulvestrant or 
placebo+fulvestrant. Primary analysis was first conducted on 10 genes based 
on pathway biology and evidence from previous studies, followed by a 
systematic panel-wide search among 2534 cancer-related genes. The 
association of gene expression with the effect of palboiclib on progression-
free survival (PFS) was evaluated using Cox regression analysis, with gene 
expression as a continuous variable or dichotomized by median. An 
independent breast cancer cohort from the Preoperative Palbociclib (POP) 
study was used for validation, with 61 patients treated with 2 weeks of 
palbociclib.  
RESULTS: In the PALOMA-3 trial, 302 patients had tumor tissue analyzed 
(palbociclib arm, 194; placebo arm, 108). Palbociclib efficacy was lower in 
patients with high versus low CCNE1 mRNA expression (median PFS: 
palbociclib arm, 7.6 mo vs 14.1 mo; placebo arm, 4.0 mo vs 4.8 mo, 
respectively; interaction P value unadjusted P=0.00238; false discovery 
adjusted P=0.0238). CCNE1 mRNA was more predictive in metastatic 
compared with archival primary biopsies. There was no significant interaction 
between treatment and expression levels of CDK4, CDK6, cyclin D1, and 
Rb1. Palbociclib was efficacious in both luminal A and B tumors. High CCNE1 
mRNA expression was associated with poor antiproliferative activity of 
palbociclib in the POP trial (P=0.005). 
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CONCLUSIONS: Addition of palbociclib to fulvestrant demonstrated efficacy 
in all biomarker groups, although high CCNE1 mRNA expression was 
associated with relative resistance to palbociclib. 
(Pfizer; NCT01942135) 
 
 
 
 
  
6 
 
Introduction 
Palbociclib is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that 
decreases retinoblastoma protein (Rb) phosphorylation, blocking cell cycle 
progression from the G1 to S phase, and reduces proliferation of breast 
cancer cells.1-3 Large randomized prospective clinical studies have 
demonstrated the efficacy and safety of palbociclib in combination with 
letrozole or fulvestrant,4-7 supporting palbociclib plus an aromatase inhibitor or 
fulvestrant as a standard of care for treating hormone receptor–positive 
(HR+), human epidermal growth factor receptor 2–negative (HER2−) 
metastatic breast cancer (MBC) in premenopausal or postmenopausal 
women.2,3,8 Extensive analyses have shown that clinical subgroups derive 
similar benefit from palbociclib combination treatment. 9-11 Identification of 
biomarkers would assist in distinguishing patient subgroups who derive the 
greatest efficacy from palbociclib, and elucidating resistance mechanisms, 
could lead to rationale selection of patients with CDK4/6 combination therapy. 
 
Preclinical research has suggested potential mechanisms of resistance to 
CDK4/6 inhibitors, including bypass activation of CDK2,12 with high cyclin E1 
(CCNE1) expression correlated with palbociclib resistance in cell line models 
of breast and ovarian cancer.13,14 Other studies have shown that CDK6 
amplification was associated with acquired resistance to CDK4/6 inhibitors15 
and that luminal subtype breast cancer cell lines were more responsive to 
CDK4/6 inhibitors than non-luminal subtypes.16 In the small nonrandomized 
Neoadjuvant Palbociclib and Anastrozole (NeoPalAna) study, exploratory 
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analysis showed that high levels of CCNE1 and CDKN2D mRNA may predict 
palbociclib resistance.17  
 
No predictive biomarkers have been identified in randomized trials of CDK4/6 
inhibitors. In PALOMA-1, neither CCND1 amplification nor p16 loss were 
predictive for palbociclib efficacy.5 In PALOMA-2, CDK4 and CDK6 
expression were not predictive of efficacy for palbociclib plus letrozole.18 In 
PALOMA-3, neither estrogen receptor 1 (ESR1) nor phosphatidylinositol-4,5-
biphosphate 3-kinase (PIK3CA) mutations predicted palbociclib plus 
fulvestrant efficacy.4,19 Additionally, data from the Preoperative Palbociclib 
(POP) study showed that PIK3CA mutations or CCND1 amplication were not 
predictive for palbociclib efficacy.20 
 
Herein, we describe an analysis of baseline tumor tissue from PALOMA-3 
using a large gene expression panel to identify predictive biomarkers for the 
relative efficacy of adding palbociclib to fulvestrant. 
 
 
Materials and Methods 
Samples 
PALOMA-3 randomized 521 patients with endocrine-pretreated MBC to 
receive palbociclib plus fulvestrant or placebo plus fulvestrant.4 This study 
was approved by an institutional review board or independent ethics 
committee at each site; all patients provided informed consent before 
enrollment. Patients consented to the assessment of biomarkers associated 
8 
 
with sensitivity or resistance to palbociclib combination treatment per study 
protocol. Except for patients with bone-only disease or relapse while on 
adjuvant therapy and who had surgery within 3 years who could provide an 
archival primary sample, all patients provided formalin-fixed paraffin-
embedded (FFPE) tissue taken from metastatic disease. One FFPE tissue 
sample (2 slides per patient) was stained with hematoxylin and eosin. A 
board-certified pathologist assessed tumor content and tissue necrosis 
(additional details in Supplement).  
 
To independently validate the association between CCNE1 mRNA expression 
and efficacy of palbociclib, we analyzed gene expression data from 61 
patients in the POP window trial (additional details in Supplement).21 This 
trial allocated women with untreated early stage breast cancer 3:1 to receive 
oral palbociclib for 14 days until the day before surgery, or no treatment. 
 
Gene Expression Analysis 
The EdgeSeq Oncology BM Panel (HTG Molecular Diagnostics; 
https://www.htgmolecular.com/assays/obp) was used for mRNA profiling, 
assessing 2534 cancer-related genes. Gene expression analysis was 
performed blinded to the clinical information. The EdgeSeq system used 
targeted capture sequencing to quantitate RNA expression levels of gene 
targets in FFPE tissues and was extensively validated (Supplementary Fig 
1). Sample preparation was conducted by following the laboratory process 
and manufacturer protocols. Sequencing was performed on the Illumina 
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NextSeq 500 Sequencer. Raw data is deposited in the Gene Expression 
Omnibus. 
 
In the POP trial, CCNE1 mRNA expression data were obtained from gene 
expression analysis on Affymetrix Human Gene ST2.1 arrays. 
 
Gene Expression Hypothesis-Driven Statistical Analysis 
Gene expression data were quantile normalized and log2 transformed  (HTG 
Molecular Diagnostics). Hypothesis-driven analysis was conducted on 10 
genes based on pathway biology and evidences from preclinical and the 
NeoPalAna studies.17 Cox regression analysis was performed to investigate 
potential interaction between biomarker levels, as a continuous variable or 
dichotomized by median level, and treatment effect in terms of PFS. 
Interaction P values were adjusted using Benjamini-Hochberg false discovery 
rate (FDR) to account for multiplicity. CCNE1 mRNA expression by treatment 
interaction was further evaluated using the nonparametric subpopulation 
treatment effect pattern plot (STEPP) method for varying levels of CCNE1 
mRNA expression22 (additional details in Supplement). Data analyses were 
performed using R and Matlab. All tests were 2-sided, unless otherwise noted. 
 
To investigate whether higher levels of CCNE1 mRNA were associated with 
lower absolute antiproliferative response (ln Ki67 of <1% at day 15) in the 
POP trial, we performed a Cochran-Armitage test for trend using the three 
tertiles of CCNE1 mRNA expression. We also performed an ANCOVA of the 
change from baseline in ln Ki67 in the palbocicib arm across the three CCNE1 
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mRNA tertiles. Analyses were carried out based on a 2-sided significance 
level of 0.05.   
 
Molecular Subtype Classification 
Only HR+ patients comprised the PALOMA-3 cohort, with no large diverse 
reference tumor sets profiled with EdgeSeq Oncology platform, limiting 
classification with PAM50, where the subtype is determined relative to a 
baseline of heterogeneous tumors.23 The Absolute Intrinsic Molecular 
Subtyping (AIMS) single sample predictor algorithm was thus applied to 
assign subtypes through a set of binary rules that compare expression 
measurements for pairs of genes from a single patient (additional details in 
Supplement).24   
 
Exploratory Unbiased Discovery Statistical Analysis 
A data-driven exploratory unbiased discovery analysis was performed for 
gene expression biomarkers suggestive of greater efficacy from adding 
palbociclib to fulvestrant. Using Cox regression analysis, the search was 
initially narrowed down to genes whose expression as a continuous variable 
was significantly associated with treatment effect within the palbociclib arm 
(P<0.01); a cross-arm interaction analysis was then performed on these 
genes. To further investigate the underlying biological processes mediating 
palbociclib plus fulvestrant response, all genes were sorted by the coefficient 
values of the expression-treatment interaction from continuous analysis 
followed by Gene Set Enrichment Analyses (GSEA; additional details in 
Supplement). 
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Results 
Gene Expression Analysis of PALOMA-3 Tumor Tissue 
In total, 462 tumor samples from 521 patients were analyzed by HTG 
EdgeSeq for gene expression (Fig 1), with 302 tumor samples evaluable for 
analysis; 159 archival primary samples (53%) and 142 metastatic biopsies 
(47%). Of the evaluable samples, 194 (64%) were from the palbociclib arm 
(102 primary, 92 metastatic samples) and 108 (36%) were from the placebo 
arm (57 primary, 50 metastatic samples). Baseline clinical and pathologic 
characteristics (Table 1) and progression free survival (Supplementary Fig 
2) were similar between the biomarker and overall PALOMA-3 populations. 
Gene expression of ESR1 mRNA and progesterone receptor (PR) mRNA 
showed high correlation with protein expression of the estrogen receptor (ER; 
Spearman R=0.54; P<0.0001) and PR (Spearman R=0.77; P<0.0001) 
assessed centrally by immunohistochemistry H score at the same time point 
(Supplementary Fig 3). ER and PR H-scores were most correlated with their 
own transcript across all genes in the EdgeSeq Oncology panel. 
 
Our primary hypothesis was that the expression of CDK4/6-RB1 axis genes 
would have an impact on the addition of palbociclib to fulvestrant. Expression 
of CDK4, CDK6, and CCND1 mRNA were not predictive of palbociclib efficacy 
(Fig 2 and Supplementary Fig 4A). Similarly, although ESR1 mRNA 
expression was prognostic with low expression associated with shorter PFS in 
both treatment arms, the efficacy of palbociclib did not differ significantly by 
ESR1 mRNA expression level (Supplementary Fig 4B). 
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CCNE1 mRNA Expression Is Predictive of Palbociclib Efficacy When 
Assessed in Metastatic Tissues 
In line with prior preclinical evidence, lower CCNE1 mRNA (cyclin E1 mRNA) 
expression was associated with improved efficacy from palbociclib (Fig 3A). 
Dividing samples by median CCNE1 mRNA  expression value, the median 
PFS of patients with high CCNE1 mRNA levels was 7.6 months with 
palbociclib plus fulvestrant and 4.0 months with placebo plus fulvestrant 
(hazard ratio [HR], 0.85; 95% CI, 0.58−1.26), while the median PFS of those 
with lower CCNE1 mRNA levels was 14.1 months with palbociclib plus 
fulvestrant and 4.8 months with placebo plus fulvestrant (HR, 0.32; 95% CI, 
0.20−0.50), with a significant interaction between treatment effect and CCNE1 
mRNA expression (unadjusted P=0.00238; false discovery adjusted 
P=0.0238; Fig 2 and Fig 3A). The interaction with CCNE1 mRNA remained 
significant after accounting for baseline clinicopathological characteristics, 
including recurrence type, tumor tissue collection site, baseline Eastern 
Cooperative Oncology Group performance status, visceral metastases, prior 
chemotherapy, prior aromatase inhibitor, and prior tamoxifen (P=0.00167). 
 
The STEPP analysis further supported a significant interaction between 
CCNE1 mRNA expression and the relative treatment effect based on the HR 
across CCNE1 mRNA expression levels (supremum HR P=0.0008; Fig 3B). 
STEPP analysis of absolute treatment effect based on 6-month PFS across 
CCNE1 mRNA expression levels consistently provided evidence of 
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heterogeneous treatment effects related to CCNE1 mRNA expression 
(P=0.016; Fig 3C).  
 
The source of tumor biopsy had an impact on the  association between 
CCNE1 mRNA expression and palbociclib efficacy. CCNE1 mRNA was highly 
predictive in metastatic biopsies (N=142; interaction P=0.00047), but marginal 
in primary biopsies (N=159; interaction P=0.09). Interestingly, primary and 
metastatic biopsies expressed similar levels of CCNE1 mRNA at baseline 
(Supplementary Table 1; P=0.57), suggesting that a more contemporaneous 
assessment of gene expression may explain the improved prediction power of 
assessment in metastatic biopsies. Tumors with documented sensitivity to 
prior hormone therapy tended to have lower CCNE1 mRNA expression levels 
(Supplementary Table 1; P=0.0032). Overall, 54% of primary and 52% of 
metastatic tumor samples were supplied by slides, while 45% of primary and 
47% of metastatic samples were supplied by blocks. As anticipated, both ER 
and PR immunohistochemistry levels were significantly higher in blocks than 
slides (P=0.00016 and P=0.004, respectively). CCNE1 mRNA levels were not 
affected by block versus slide tissue type analyzed (slide versus block 
P=0.085). 
 
Independent Validation of high CCNE1 mRNA as a Marker of Palbociclib 
Resistance in the POP Trial 
In the POP trial, high CCNE1 mRNA expression was associated with lower 
absolute anti-proliferative response to palbociclib (high CCNE1 mRNA, 36% 
versus, intermediate CCNE1 mRNA, 79%, and low CCNE1 mRNA, 80%; 
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P=0.005; Figure 4A). High CCNE1 mRNA expression was also associated 
with a reduced geometric mean change in Ki67 with palbociclib treatment 
(high CCNE1 mRNA, –49% versus, intermediate CCNE1 mRNA, –82%, and 
low CCNE1 mRNA, –82%;  P=0.015; Figure 4B) 
 
Intrinsic Subtypes and Efficacy of Palbociclib  
Of tumors with gene expression data, 133 (44%) were luminal A, 93 (31%) 
luminal B, and 76 (25%) non-luminal (5 basal-like, 63 HER2-enriched, 8 
normal-like; Fig 5A). In patients with luminal A tumors, median PFS was 16.6 
months with palbociclib plus fulvestrant and 4.8 months with placebo plus 
fulvestrant (HR, 0.41; 95% CI, 0.25−0.66), while in patients with luminal B 
tumors, median PFS was 9.2 months with palbociclib plus fulvestrant and 3.5 
months with placebo plus fulvestrant (HR, 0.64; 95% CI, 0.38−1.09; Fig 5B). 
There was no significant interaction between luminal A versus luminal B and 
treatment effect of palbociclib (P=0.20). Patients with non-luminal HR+ tumors 
had a median PFS of 9.5 months with palbociclib plus fulvestrant and 5.5 
months with placebo plus fulvestrant (HR, 0.58; 95% CI, 0.34−0.99; 
Supplementary Fig 5). 
 
CCNE1 mRNA expression appeared highest in the few basal-like subtype 
tumors, followed by luminal B (across all subtypes, P<0.0001; Fig 5C; 
Supplementary Table 1). The CCNE1 mRNA expression level of luminal A 
tumors was significantly lower than luminal B (P<0.0001, Mann-Whitney test). 
In an exploratory subtype-specific analysis, the effect of CCNE1 mRNA as a 
continuous variable on improvement in PFS from adding palbociclib to 
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fulvestrant was apparent in both luminal B and non-luminal subtypes 
(interaction P=0.03 and 0.007 respectively), but not luminal A (interaction 
P=0.49).   
 
Discovery Analysis of Genes and Pathways Associated With Efficacy of 
Palbociclib  
After correcting for multiple hypothesis testing, 20 candidate genes were 
identified with FDR<0.1, including 11 relative resistance markers and 9 
relative sensitivity markers (Supplementary Table 2). The unbiased search 
independently identified high CCNE1 mRNA expression as the second most 
significant gene panel-wide linked to lack of efficacy from the addition of 
palbociclib to fulvestrant. The only more significant gene was Neuromedin U, 
which had previously been implicated in drug resistant HER2+ breast cancer 
by driving increased levels of TGFβ125 and expanding the cancer stem cell 
phenotype.26 We noted that higher CDKN2D mRNA (p19) expression level 
was also associated with reduced efficacy with palbociclib combination, as 
well as possibly CDKN2C mRNA (p18) expression (Supplementary Fig 6).  
Both genes belong to the INK4 family, which regulates kinase activities of 
CDK4/6. 
 
Among the 50 hallmark gene sets from the Molecular Signature Database 
(MSigDB),27 E2F targets (regulon) demonstrated the most significant 
association with lack of improvement in PFS from palbociclib combination 
(NES=−2.36; FDR<0.001), followed by other cell cycle-related pathways, 
including Myc regulon, mechanistic target of rapamycin complex 1 (mTORC1) 
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signaling, G2/M checkpoint, DNA repair, and mitotic spindle  (Supplementary 
Fig 7). These results from the unbiased search support and confirm the 
critical role of E2F transcriptional activity, and CCNE1 mRNA in particular, in 
determining the relative clinical efficacy from the addition of palbociclib to 
fulvestrant. 
 
Discussion  
We present a gene expression analysis of breast cancer tissues in the 
PALOMA-3 trial and identified the first predictive marker of efficacy from 
CDK4/6 inhibition, with low expression of CCNE1 mRNA associated with 
greater efficacy of palbociclib. Low E2F transcriptional activity was associated 
with relative improved efficacy, with CCNE1 mRNA appearing to be the most 
significant predictive biomarker gene within the regulon. In contrast, we found 
no evidence that either ER expression or luminal subtype associated with 
efficacy of palbociclib.  
 
Previous studies have shown discordance between primary and metastatic 
biopsies in genetic profiles 28and HER229 and ER and PR status.30 PALOMA-
3 was one of the first phase 3 trials to mandate the provision of recurrent 
disease biopsies, unless patients had bone-only disease or relapsed in the 
first 3 years of adjuvant endocrine therapy and could provide tissue from the 
primary tumor. Our results demonstrate that the collection of tissue temporally 
closer to the time of trial entry greatly facilitates the identification of predictive 
markers and could be considered a norm in all phase 3 advanced breast 
cancer trials. 
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Cyclin E1 canonically activates CDK2,31 and our findings build on a wealth of 
preclinical and early clinical evidence that cyclin E1 expression is a marker of 
resistance to CDK4/6 inhibition.13,14,17,32 High CCNE1 mRNA expression 
correlates with resistance to therapy in cell line models of breast and ovarian 
cancer.13,14 In triple negative cancer cell lines with resistance to CDK4/6 
inhibition, CCNE1 mRNA expression remains high directly after mitosis, 
bypassing the restriction point at which CDK4/6 has traditionally been viewed 
as being required for G1 transition by activating CDK2.33 High expression of 
low molecular weight cyclin E1 assessed by immunohistochemistry was 
associated with poor outcomes,  including in a cohort of patients treated with 
palbociclib in routine clinical practice,34 35 It will be interesting in future 
research to explore the relative importance of assessing CCNE1 mRNA 
versus cyclin E1 protein, and the post-translational modification of cyclin E1.  
 
We independently validated high CCNE1 mRNA as a resistance biomarker in 
the POP trial. The POP trial assessed gene expression with Affymetrix arrays, 
demonstrating the potential of CCNE1 mRNA expression to be predictive 
across different platforms.Limited biomarker work from other preoperative 
palbociclib trials also supports high CCNE1 mRNA as a biomarker identifying 
ER+ and HER2− cancers that are resistant to CDK4/6 inhibition.17 These data 
suggest that CCNE1 mRNA expression may be associated with the benefit 
from palbociclib in early stage breast cancer. Future research will be required 
to assess to the impact endocrine therapy resistance on CCNE1 mRNA 
expression, and to identify the cellular processes that allow CCNE1 mRNA 
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expression to become decoupled from the requirement for prior CDK4/6 
activation. 
 
Overall, both luminal A and B breast cancer subtypes derived benefit from 
adding palbociclib to fulvestrant. Our data add to recent data that the small 
subset of non-luminal ER+ breast cancers may be a distinct and separate 
entity characterized by disparate treatment responsiveness.16,36 Non-luminal 
ER+ breast cancers may derive less benefit from endocrine therapy 
compared with luminal breast cancers.37 Our data suggest that CDK4/6 
inhibition combination therapy may improve PFS in non-luminal cancers, 
which were dominated by the HER2-enriched phenotype (Supplementary 
Fig 5). In unsupervised exploratory analysis of genes and pathways 
associated with palbociclib efficacy, we identified a potential association 
between high expression levels of p19-CDKN2D mRNA, as well as p18-
CDKN2C mRNA, and reduced efficacy from palbociclib. This observation is 
exploratory and requires validation, but possibly identifies that high levels of 
an intrinsic CDK4/6 inhibitor may predict lower response to palbociclib. 
mTORC1 signaling was associated with reduced response to palbociclib 
addition, consistent with previous pre-clincial studies.38  
   
Our study has important limitations. The PALOMA-3 backbone endocrine 
therapy was fulvestrant,4,7 and it is unknown if the biomarkers identified in this 
study are relevant to aromatase inhibitor-CDK4/6 combinations. Our analysis 
was not conducted with a clinical assay and should not be used to select 
patients for therapy without further validation of the results and validation of 
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clinical grade diagnostics. In addition, it is not clear from this analysis if 
measuring CCNE1 mRNA would be useful to make decisions for individual 
patients, as the subgroup with high CCNE1 mRNA expression potentially 
derived some PFS improvement with the addition of palbociclib to fulvestrant, 
albeit to a substantially less degree than cancers of low expression.  
 
In this correlative analysis of the PALOMA-3 trial, we have identified the first 
potential biomarker that was predictive of the efficacy of palbociclib. Our 
findings reinforce CDK2 as a key bypass kinase of CDK4/6 inhibition, 
identifying potential therapeutic approaches to prevent early progression on 
CDK4/6 inhibitors. The effect of CCNE1 mRNA expression was most evident 
in metastatic biopsies, which are more contemporaneous to treatment than 
archival primary biopsies, demonstrating the importance of collecting 
metastatic/recurrent tissue biopsies in clinical studies. Further methodologic 
and clinical validations are warranted to elucidate the role of CCNE1 mRNA 
expression as a biomarker pf CDK4/6 inhibitor therapy. 
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Table 1. Baseline Clinical and Pathological Characteristics of the Biomarker 
Subset and Overall Intent-to-Treat Population From PALOMA-3 
 Intention-to-Treat Population, n (%) Biomarker Subset, n (%) 
 FUL+PAL 
(n=347) 
FUL+PBO 
(n=174) 
FUL+PAL 
(n=194) 
FUL+PBO 
(n=108) 
Recurrence type     
     Recurrent 
     Newly diagnosed 
278 (80) 
67 (19) 
146 (84) 
25 (14) 
160 (82) 
32 (16) 
90 (83) 
15 (14) 
Visceral metastasis     
     Yes 
     No 
200 (58) 
147 (42) 
104 (60) 
70 (40) 
108 (56) 
86 (44) 
60 (56) 
48 (44) 
Prior chemotherapy     
     Yes 
     No 
253 (73) 
94 (27) 
138 (79) 
36 (21) 
144 (74) 
50 (26) 
87 (81) 
21 (19) 
Prior AI     
     Yes 
     No 
296 (85) 
51 (15) 
151 (87) 
23 (13) 
168 (87) 
26 (13) 
91 (84) 
17 (16) 
Prior tamoxifen     
     Yes 
     No 
210 (61) 
137 (39) 
104 (60) 
70 (40) 
111 (57) 
83 (43) 
66 (61) 
42 (39) 
Baseline ECOG 
performance status 
    
     0 
     1 
206 (59) 
141 (41) 
116 (67) 
58 (33) 
110 (57) 
84 (43) 
70 (65) 
38 (35) 
ER/PgR status     
     ER-/PgR+ 
     ER+/PgR- 
     ER+/PgR+ 
1 (0) 
92 (27) 
240 (69) 
2 (1) 
50 (29) 
111 (64) 
0 (0) 
48 (25) 
137 (71) 
1 (1) 
24 (22) 
76 (70) 
Menopausal status     
     Pre/perimenopausal 
     Postmenopausal 
72 (21) 
275 (79) 
36 (21) 
138 (79) 
32 (16) 
162 (84) 
21 (19) 
87 (81) 
Documented sensitivity to 
prior hormone therapy 
    
     Yes 
     No 
273 (79) 
74 (21) 
133 (76) 
41 (24) 
150 (77) 
44 (23) 
82 (76) 
26 (24) 
Measurable disease 
Present at baseline 
    
     Yes 
     No 
267 (77) 
80 (23) 
138 (79) 
36 (21) 
143 (74) 
51 (26) 
83 (77) 
25 (23) 
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AI=aromatase inhibitor; ECOG=Eastern Cooperative Oncology Group; ER=estrogen receptor; 
FUL=fulvestrant; PAL=palbociclib; PBO=placebo; PgR=progesterone receptor.  
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Figures 
 
 
 
 
Fig 1. CONSORT diagram of breast cancer tissues analyzed for gene 
expression. ITT=intent-to-treat. 
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Fig 2. Association of cell cycle pathway gene expression and the efficacy of 
palbociclib in combination with fulvestrant.  
Expression of cell cycle pathway genes, dichotomized by median expression, 
with HRs for PFS of palbociclib plus fulvestrant versus placebo plus 
fulvestrant. HRs were derived with a Cox regression model. Interaction P 
value for statistical interaction between gene expression and treatment. 
CCND1=cyclin-D1; CCND3=cyclin-D3; CCNE1=cyclin-E1; CCNE2=cyclin-E2; 
CDK2=cyclin-dependent kinase 2; CDK4=cyclin-dependent kinase 4; 
CDK6=cyclin-dependent kinase 6; CDKN2A=cyclin-dependent kinase inhibitor 
2A; CI=confidence interval; ESR1=estrogen receptor 1; FDR=false discovery 
rate; FUL=fulvestrant; HR=hazard ratio; mRNA=messenger ribonucleic acid; 
PAL=palbociclib; PBO=placebo; PFS=progression-free survival; 
RB1=retinoblastoma 1. 
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Fig 3. Association between CCNE1 mRNA expression and palbociclib 
efficacy. 
(A) PFS in tumors with low or high CCNE1 mRNA expression by median. HRs 
were derived with a Cox regression model. P value from the interaction test 
between gene expression and treatment. (B) STEPP analysis of CCNE1 
mRNA expression as measured by HR (palbociclib plus fulvestrant versus 
placebo plus fulvestrant). The x-axis represents the median CCNE1 mRNA 
expression for patients in each of the overlapping subpopulations. The 
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dashed lines represent the corresponding 95% pointwise confidence intervals. 
The horizontal solid black line indicates a reference HR of 1 with HR<1 
favoring palbociclib plus fulvestrant combination. (C) STEPP analysis of 
CCNE1 mRNA expression as measured by 6-month PFS rates. 
CCNE1=cyclin E1; CI=confidence interval; FUL=fulvestrant; HR=hazard ratio; 
mPFS=median PFS; PAL=palbociclib; PBO=placebo; PFS=progression-free 
survival; STEPP=subpopulation treatment effect pattern plot. 
 
 
 
Fig 4. Independent validation of high CCNE1 mRNA as a marker of 
palbociclib resistance in the POP trial. (A) Anti-proliferative response by 
CCNE1 expression tertile. (B) Geometric mean change in Ki67 expression 
with palbociclib treatment by CCNE1 expression tertile.CCNE1=cyclin E1. 
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Fig 5. Intrinsic molecular subtype and efficacy of palbociclib. (A) Intrinsic 
subtype distribution of tumors in PALOMA-3. (B) Progression-free survival in 
luminal A and B tumors. (C) CCNE1 mRNA expression by intrinsic molecular 
subtype. 
BasalL=basal-like; CCNE1=cyclin E1; FUL=fulvestrant; Her2E=human 
epidermal growth factor receptor 2-enriched; HR=hazard ratio; LumA=luminal 
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A; LumB=luminal B; mPFS=median progression-free survival; 
mRNA=messenger ribonucleic acid; NormL=normal-like; PAL=palbociclib; 
PBO=placebo; PFS=progression-free survival. 
 
 
 
 
 
 
 
